Can Donor-Derived Cell-Free DNA Detect Graft-Versus-Host Disease in Solid Organ Transplantation: A Case Report

Williams, M. D.; Thomas, Johnson; Paner, Agne; Chan, Edie Y.; Hollinger, Edward F.; Schadde, Erik; Hertl, Martin; Varughese, Christy; Olaitan, Oyedolamu

doi:10.1016/j.transproceed.2021.11.014

Cited by 3 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One patient dropped out because of pregnancy, another was excluded because of developing graft-versus-host disease. 13 Forty-six patients were included in the data analysis. Median age was 53.2.…”

Section: Resultsmentioning

confidence: 99%

Early Experience Using Donor-derived Cell-free DNA for Surveillance of Rejection Following Simultaneous Pancreas and Kidney Transplantation

Williams

Fei

Schadde

et al. 2022

Transplantation Direct

Self Cite

View full text Add to dashboard Cite

Background. Allograft biopsy is the gold standard for diagnosing graft rejection following simultaneous pancreas and kidney (SPK) transplant. Intraperitoneal biopsies are technically challenging and can be burdensome to patients and the healthcare system. Donor-derived cell-free DNA (dd-cfDNA) is well-studied in kidney transplant recipients; however, it has not yet been studied in the SPK population. Methods. We hypothesized that dd-cfDNA could be utilized for rejection surveillance following SPK transplant. We prospectively collected dd-cfDNA in 46 SPK patients at a single institution. Results. There were 10 rejection events, 5 of which were confirmed with biopsy. The other 5 were treated based on dd-cfDNA and clinical data alone with favorable outcomes. Among all patients who did not have rejection, 97% had dd-cfDNA <0.5%. Dd-cfDNA may also help differentiate rejection from graft injury (ie, pancreatitis) with median values in rejection 2.25%, injury 0.36%, and quiescence 0.18% (P = 0.0006). Conclusions. Similar to kidneys, dd-cfDNA shows promise for rejection surveillance in SPK transplant recipients.

show abstract

Section: Resultsmentioning

confidence: 99%

Early Experience Using Donor-derived Cell-free DNA for Surveillance of Rejection Following Simultaneous Pancreas and Kidney Transplantation

Williams

Fei

Schadde

et al. 2022

Transplantation Direct

Self Cite

View full text Add to dashboard Cite

show abstract

“…We recently published a case report which described a patient who experienced profound altered mental status for one month prior to manifesting classic GVHD symptoms. 2 Another case report published last year describes a patient with GVHD one month after liver transplant; this patient presented with classic GVHD symptoms, however, he also had encephalitis and unilateral extremity weakness. 3 Neurologic symptoms have been reported in GVHD following stem cell transplant as well.…”

mentioning

confidence: 99%

Opportunities to Improve Outcomes of Graft-Versus-Host Disease in Solid Organ Transplantation

Williams

Olaitan

2022

Prog Transpl

Self Cite

View full text Add to dashboard Cite

Multiple drugs

2023

Reactions Weekly

View full text Add to dashboard Cite

Can Donor-Derived Cell-Free DNA Detect Graft-Versus-Host Disease in Solid Organ Transplantation: A Case Report

Cited by 3 publications

References 12 publications

Early Experience Using Donor-derived Cell-free DNA for Surveillance of Rejection Following Simultaneous Pancreas and Kidney Transplantation

Early Experience Using Donor-derived Cell-free DNA for Surveillance of Rejection Following Simultaneous Pancreas and Kidney Transplantation

Opportunities to Improve Outcomes of Graft-Versus-Host Disease in Solid Organ Transplantation

Multiple drugs

Contact Info

Product

Resources

About